TY - JOUR
T1 - Comparison of short-course versus long-course whole-brain radiotherapy in the treatment of brain metastases
AU - Rades, Dirk
AU - Bohlen, Guenther
AU - Dunst, Juergen
AU - Lohynska, Radka
AU - Veninga, Theo
AU - Stalpers, Lukas
AU - Schild, Steven E.
AU - Dahm-Daphi, Jochen
PY - 2008/1
Y1 - 2008/1
N2 - Background and Purpose: Whole-brain radiotherapy (WBRT) is the most common treatment for brain metastases. Most of these patients have a poor survival prognosis. Therefore, a short radiation program is preferred, if it provides a similar outcome as longer programs. This study compares 20 Gy in five fractions (treatment time: 1 week) to longer programs, with higher doses including 30 Gy in ten fractions (2 weeks) and 40 Gy in 20 fractions (4 weeks). Patients and Methods: Data regarding 1,085 patients treated with WBRT for brain metastases were retrospectively analyzed. 387 patients received 20 Gy in five fractions, and 698 patients received higher doses (30 Gy in ten fractions, n = 527, or 40 Gy in 20 fractions, n = 171). In addition, eight potential prognostic factors were investigated including age, sex, Karnofsky Performance Score (KPS), tumor type, interval from tumor diagnosis to WBRT, number of brain metastases, extracranial metastases, and recursive partitioning analysis (RPA) class. Subgroup analyses were performed for each RPA class individually. Results: The WBRT schedule had no significant impact on survival (p = 0.415). On multivariate analysis, improved survival was significantly associated with age ≤ 60 years (risk ratio [RR]: 1.28; p < 0.001), KPS ≥ 70 (RR: 1.73; p = 0.002), lack of extracranial metastases (RR: 1.27; p = 0.007), interval from tumor diagnosis to WBRT > 8 months (RR: 1.19; p = 0.011), and lower RPA class (RR: 1.56; p < 0.001). The subgroup analyses for each RPA class did not reveal a significant association between WBRT schedule and survival. Conclusion: Short-course WBRT with 20 Gy in five fractions is preferable for most patients, because it is associated with similar survival as longer programs and is less time-consuming.
AB - Background and Purpose: Whole-brain radiotherapy (WBRT) is the most common treatment for brain metastases. Most of these patients have a poor survival prognosis. Therefore, a short radiation program is preferred, if it provides a similar outcome as longer programs. This study compares 20 Gy in five fractions (treatment time: 1 week) to longer programs, with higher doses including 30 Gy in ten fractions (2 weeks) and 40 Gy in 20 fractions (4 weeks). Patients and Methods: Data regarding 1,085 patients treated with WBRT for brain metastases were retrospectively analyzed. 387 patients received 20 Gy in five fractions, and 698 patients received higher doses (30 Gy in ten fractions, n = 527, or 40 Gy in 20 fractions, n = 171). In addition, eight potential prognostic factors were investigated including age, sex, Karnofsky Performance Score (KPS), tumor type, interval from tumor diagnosis to WBRT, number of brain metastases, extracranial metastases, and recursive partitioning analysis (RPA) class. Subgroup analyses were performed for each RPA class individually. Results: The WBRT schedule had no significant impact on survival (p = 0.415). On multivariate analysis, improved survival was significantly associated with age ≤ 60 years (risk ratio [RR]: 1.28; p < 0.001), KPS ≥ 70 (RR: 1.73; p = 0.002), lack of extracranial metastases (RR: 1.27; p = 0.007), interval from tumor diagnosis to WBRT > 8 months (RR: 1.19; p = 0.011), and lower RPA class (RR: 1.56; p < 0.001). The subgroup analyses for each RPA class did not reveal a significant association between WBRT schedule and survival. Conclusion: Short-course WBRT with 20 Gy in five fractions is preferable for most patients, because it is associated with similar survival as longer programs and is less time-consuming.
KW - Brain metastases
KW - RPA class
KW - Survival
KW - Whole-brain radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=38149017853&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38149017853&partnerID=8YFLogxK
U2 - 10.1007/s00066-008-1795-5
DO - 10.1007/s00066-008-1795-5
M3 - Article
C2 - 18188520
AN - SCOPUS:38149017853
SN - 0179-7158
VL - 184
SP - 30
EP - 35
JO - Strahlentherapie und Onkologie
JF - Strahlentherapie und Onkologie
IS - 1
ER -